News and Announcements
Bioactive Laboratories FY16 Update – Welcomes New Investors, Kicks Off New Drug Development Project & Celebrates TGA Milestone
- Published July 11, 2016 3:03PM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Bioactive Laboratories welcomes its new investors & continues to invite SMSF investors to its register.
The Drug Development Division is powering ahead with the New Molecule Discovery project at the Eskitis Institute. The significance of this project, in creating a compound library, will add to Bioactive’s IP register of patents for commercial licensing.
The Complementary Medicine Division, creating optimised extracts, submitted its TGA New Substance application in June. This important milestone firms up customer relationships and opens the door to an FDA submission in the new financial year.
Bioactive have discovered new plant sourced molecules creating first-in-class stomach friendly anti-inflammatory and anti-microbial agents. These collectively service the global market of 7 billion people. An investor exit is planned within 2 years.
Company Updates
Capital Is Flowing – Just Not to Everyone: Inside Australia’s $1.8 Billion Q1 2026
Australia’s startup ecosystem opened 2026 with a number that demanded attention. In the first three months of the year, $1.8 billion was raised across 81 venture deals and 26 accelerator rounds. That makes Q1 2026 the strongest start to a year since the 2022 boom, up 63% on Q1 2025, and more than double the […]
The control layer for the electrified home
THE MARKET SHIFT Australian households have been pulled into a real-time energy market they never knowingly signed up for. Flat electricity tariffs are disappearing. In their place: dynamic, time-of-use pricing that changes depending on when power is consumed. Electricity is now cheapest when solar floods the grid in the middle of the day — and […]
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
Backed By Leading Investment Groups and Family Offices
